OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Clinical Microbiology & Infectious Diseases is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection	496
Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome	204
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review	116
Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship	95
Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France	86
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile	82
Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions	61
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa	57
Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review	54
Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit	49
Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae	48
Antimicrobial resistance in Clostridioides difficile	47
Effectiveness of favipiravir in COVID-19: a live systematic review	45
Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting	43
Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19	38
The role of potentiating mutations in the evolution of pandemic Escherichia coli clones	37
Multinational evaluation of the BioFire® FilmArray® Pneumonia plus Panel as compared to standard of care testing	37
Expression and co-expression analyses of TMPRSS2, a key element in COVID-19	37
Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection	37
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays	35
Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: an international ID-IRI survey	33
Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015–2019	33
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects	32
Application of metagenomic next-generation sequencing in the diagnosis and treatment guidance of Pneumocystis jirovecii pneumonia in renal transplant recipients	31
Chlorhexidine leads to the evolution of antibiotic-resistant Pseudomonas aeruginosa	30

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants	29
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, a	27